🔍

AUROPHARMA - Aurobindo Pharma

📊 NSE: AUROPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:43

📢 Recent Corporate Announcements

Aurobindo Pharma Faces ₹77.6 Cr GST Demand and Equal Penalty; To Appeal in GSTAT

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 13 Mar 2026, 12:54 PM

Aurobindo Pharma has received an order from the GST Appellate Authority confirming a tax demand of ₹77.61 crore and an equivalent penalty of ₹77.61 crore. The dispute pertains to alleged excess IGST refunds and non-reversal of Input Tax Credit (ITC) for the period between July 2017 and March 2020. While the authority dropped the interest demand on ITC reversal, the primary tax and penalty were upheld. The company has already paid ₹23.72 crore under protest and intends to challenge the ruling at the GST Appellate Tribunal (GSTAT).

GST demand of ₹77.61 crore confirmed along with a matching penalty of ₹77.61 crore.
Issues involve excess IGST refund (CIF vs FOB) and non-reversal of ITC under Rule 37 for FY 2017-2020.
Company has already deposited ₹23.72 crore under protest and reversed ₹8.78 crore in ITC.
Appellate Authority dropped the demand for interest on ITC reversal while upholding other charges.
Aurobindo Pharma plans to file an appeal before the Goods and Services Tax Appellate Tribunal (GSTAT).

💡 Investors should monitor the outcome of the GSTAT appeal as the total potential liability exceeds ₹150 crore. While the company maintains there is no material impact, persistent tax litigation can weigh on short-term sentiment.

Aurobindo Pharma Subsidiary Unit-IV Receives VAI Status from US FDA

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 12 Mar 2026, 09:49 AM

Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited, has received an Establishment Inspection Report (EIR) for its Unit-IV facility in Andhra Pradesh. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI), effectively closing the inspection that took place in December 2025. This follows the initial issuance of a Form 483 with 5 observations at the conclusion of the audit. The VAI classification is a positive outcome, indicating that the regulatory hurdles for this specific unit are resolved for the current cycle.

US FDA inspected APL Healthcare Unit-IV from December 8 to December 17, 2025
The inspection initially resulted in a Form 483 containing 05 observations
Facility has now been classified as Voluntary Action Indicated (VAI) by the US FDA
The receipt of the EIR signifies that the regulatory inspection for this unit is now officially closed
Unit-IV is located in SPSR Nellore District, Andhra Pradesh, and is a 100% subsidiary of Aurobindo Pharma

💡 Investors should view this as a positive development as it clears a regulatory hurdle for a key manufacturing unit. This reduces compliance risk and paves the way for potential new product approvals from this facility.

Aurobindo Pharma to Host Investor Group Plant Visit in Vizag and Kakinada on March 16

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 01:22 PM

Aurobindo Pharma has scheduled an in-person plant visit for an analyst and investor group on March 16, 2026. The visit will take place at the company's facilities in Vizag and Kakinada from 9:00 AM to 5:00 PM IST. This event allows institutional investors to gain direct insights into the company's manufacturing capabilities and operational scale. The company clarified that no unpublished price sensitive information (UPSI) will be disclosed during these interactions.

Scheduled plant visit for analysts and investor groups on March 16, 2026
The visit will cover manufacturing facilities located in Vizag and Kakinada
The interaction is scheduled for a full day, from 09:00 AM to 05:00 PM IST
Company confirms that no unpublished price sensitive information (UPSI) will be shared

💡 No immediate action is required as this is a routine investor relations event. Investors should monitor for any post-visit reports from participating analysts regarding operational efficiency.

Aurobindo Pharma Schedules Analyst and Investor Plant Visit to Vizag and Kakinada

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 01:19 PM

Aurobindo Pharma Limited has scheduled an in-person plant visit for a group of analysts and investors on March 16, 2026. The visit will cover the company's facilities in Vizag and Kakinada, running from 9:00 AM to 5:00 PM IST. Such visits are standard practice to allow institutional stakeholders to observe operational infrastructure and manufacturing capabilities. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the interaction.

In-person plant visit scheduled for March 16, 2026, for analyst and investor groups.
The visit will take place at manufacturing sites in Vizag and Kakinada.
The interaction is scheduled for a full day from 09:00 AM to 05:00 PM IST.
Company confirms that no unpublished price sensitive information (UPSI) will be discussed.

💡 This is a routine investor relations event; no immediate action is necessary. Investors may look for subsequent research notes from participating brokerages for qualitative insights into the company's manufacturing operations.

Aurobindo Pharma to Participate in BofA Investor Meeting in Singapore on March 13

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Mar 2026, 02:45 PM

Aurobindo Pharma has announced its participation in an upcoming investor meeting scheduled for March 13, 2026. The event is an in-person group meeting organized by Bank of America (BofA) and will take place in Singapore. The session is slated for one hour, from 09:00 AM to 10:00 AM SGT. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be discussed during these interactions.

In-person group investor meeting scheduled for March 13, 2026
Meeting organized by Bank of America (BofA) in Singapore
Scheduled time slot is 09:00 AM to 10:00 AM SGT
Company confirms no unpublished price sensitive information (UPSI) will be shared

💡 This is a routine investor engagement activity; no immediate action is required. Investors may look for any subsequent corporate presentations or transcripts if the company chooses to release them.

Aurobindo Pharma Launches Generic Pomalyst in US Targeting $3.3 Billion Market

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 04 Mar 2026, 12:13 PM

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma, has launched Pomalidomide Capsules in the US market. The product is a generic version of BMS Pharmaceuticals' Pomalyst, which has an estimated annual market size of $3.3 billion as of January 2026. As a First-to-File (FTF) applicant, Eugia is well-positioned to capture significant market share in this high-value oncology segment. The product will be manufactured at the company's Eugia Unit-I facility, supporting its specialty portfolio growth.

Launched Pomalidomide Capsules in 1 mg, 2 mg, 3 mg, and 4 mg strengths in the US
Targets a substantial US market size of approximately $3.3 billion according to IQVIA MAT data
Eugia Pharma was one of the First-to-File (FTF) ANDA applicants for this product
The product is the generic equivalent of Pomalyst by BMS Pharmaceuticals Corp
Manufacturing will be handled at the Eugia Unit-I facility

💡 Investors should monitor the market share gains in the US oncology segment as this launch represents a significant revenue opportunity. The FTF status provides a competitive edge that could bolster margins in the upcoming quarters.

Aurobindo Pharma to Participate in Goldman Sachs India Pharma Corporate Days on March 6

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 12:18 PM

Aurobindo Pharma has announced its participation in the Goldman Sachs India Pharma Corporate Days scheduled for March 6, 2026. The virtual meeting will take place from 2:00 PM to 5:00 PM IST and involves senior company officials. This is a routine engagement with institutional investors and analysts to discuss publicly available information. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the session.

Participation in Goldman Sachs India Pharma Corporate Days on March 6, 2026
Meeting scheduled for a 3-hour duration from 02:00 PM to 05:00 PM IST
Interaction will be conducted via a virtual/online platform
Company confirmed that no unpublished price sensitive information (UPSI) will be discussed

💡 No immediate action is required as this is a routine investor interaction. Investors may look for any subsequent corporate presentations or transcripts that might offer qualitative insights into the company's operational strategy.

Aurobindo Pharma Director P. Sarath Chandra Reddy Discharged in Delhi Liquor Case

🟢 POSITIVE ⭐ 7/10

LEGAL 📅 02 Mar 2026, 09:52 AM

Aurobindo Pharma has confirmed that its Non-Executive Director, Mr. P. Sarath Chandra Reddy, has been discharged by a Special CBI Court in the Delhi Liquor Excise Policy case. The court found no evidence of conspiracy, illegal gratification, or unlawful benefits involving Mr. Reddy after examining material from the CBI's supplementary chargesheet dated July 29, 2024. This discharge applies to all charges leveled by the CBI, effectively removing a significant legal and reputational overhang that had persisted since late 2022. The court specifically noted a lack of basis for including him as an accused in the case.

Special CBI Court discharged Mr. P. Sarath Chandra Reddy and 22 others on February 27, 2026
Court found no material evidence of participation in conspiracy or payment of illegal gratification
Mr. Reddy was originally added as Accused No. 23 in a supplementary chargesheet dated July 29, 2024
The discharge follows two months of day-to-day arguments and extensive evidence examination
The court questioned the basis on which Mr. Reddy was arrayed as an accused in the first place

💡 This is a positive development as it clears a key board member from a high-profile legal controversy, reducing corporate governance concerns. Investors can now focus back on the company's fundamental performance and USFDA compliance status.

Aurobindo Pharma Subsidiary Eugia Unit-I US FDA Inspection Ends with 4 Observations

🔵 WATCH ⭐ 7/10

REGULATORY 📅 27 Feb 2026, 04:09 PM

The US FDA conducted a regulatory inspection at Unit-I of Eugia Pharma Specialities Ltd, a wholly owned subsidiary of Aurobindo Pharma, between February 16 and February 27, 2026. The inspection of this formulation manufacturing facility in Telangana concluded with 4 observations. The company intends to respond to these observations within the stipulated timelines and has stated there is no immediate impact on financials or operations. Investors should monitor the classification of these observations as they can influence future product approvals from this facility.

US FDA inspection of Eugia Unit-I formulation facility took place from February 16 to February 27, 2026
The inspection concluded with 4 observations issued by the regulatory authority
Eugia Pharma Specialities Ltd is a 100% wholly owned subsidiary of Aurobindo Pharma Limited
Company confirms no current quantifiable impact on financials or operations due to the observations

💡 Investors should wait for the US FDA's final classification of the inspection (NAI, VAI, or OAI) to determine the severity of the 4 observations. While the company claims no immediate impact, any escalation to a Warning Letter could affect the launch pipeline from this unit.

Aurobindo Pharma Subsidiary Receives USFDA Approval for Everolimus Tablets ($78M Market)

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 26 Feb 2026, 11:47 AM

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities, has received final USFDA approval for Everolimus Tablets, a generic version of Novartis' Zortress. The approved product is indicated for the prophylaxis of organ rejection in kidney and liver transplant patients. The market size for this medication is estimated at approximately US$ 78 million for the 12 months ending December 2025. This approval marks the 184th ANDA for the Eugia group, with a commercial launch planned for Q1FY27.

Final USFDA approval for Everolimus Tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths.
Estimated annual market size of US$ 78 million according to IQVIA MAT December 2025 data.
Commercial launch is expected to commence in Q1FY27 from the Eugia Unit-I facility.
Represents the 184th ANDA approval for the Eugia Pharma Specialities Group.
Product is bioequivalent and therapeutically equivalent to the reference drug Zortress by Novartis.

💡 Investors should monitor the timely launch in Q1FY27 as this adds to Aurobindo's specialty portfolio in the US market. The approval reinforces the company's execution capabilities in the complex generics and specialty segment through its subsidiary Eugia.

Aurobindo Pharma Incorporates New Subsidiary Engenra Biologics for CDMO Expansion

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 24 Feb 2026, 04:28 PM

Aurobindo Pharma has incorporated a new wholly-owned subsidiary, Engenra Biologics Private Limited, in India on February 24, 2026. The subsidiary is established with an initial cash subscription of Rs. 10 lakhs, representing 1,00,000 equity shares at Rs. 10 each. The primary objective of this new entity is to expand the company's contract manufacturing (CDMO) and other pharmaceutical manufacturing operations. This move signals Aurobindo's intent to scale its specialized manufacturing capabilities within the domestic market.

Incorporation of Engenra Biologics Private Limited as a 100% wholly-owned subsidiary
Initial capital investment of Rs. 10 lakhs divided into 1,00,000 equity shares
Strategic focus on expanding contract manufacturing and pharmaceutical operations
Entity incorporated in India with 100% control and no prior turnover history
Transaction conducted at arms-length with no promoter group interest

💡 Investors should monitor the scale of capital expenditure and future contract wins under this new subsidiary as it indicates Aurobindo's growth trajectory in the CDMO space. The stock remains a watch for long-term expansion in specialized manufacturing.

Aurobindo Pharma Receives ₹169.84 Crore GST Demand and Penalty Order

🔴 NEGATIVE ⭐ 6/10

REGULATORY 📅 19 Feb 2026, 03:13 PM

Aurobindo Pharma has been served with four orders from the GST Department demanding the recovery of ₹169.84 crores in previously granted refunds. The demand includes ₹84.92 crores in GST and an equivalent penalty of ₹84.92 crores for the period of September to December 2022. The dispute involves the calculation of Input Tax Credit (ITC) refunds for its EOU Unit 3, which the department alleges were erroneous. The company intends to contest this demand through an appeal, stating that there is no material impact on its current operations.

Total disputed amount stands at ₹169.84 crores, including a 100% penalty of ₹84.92 crores.
The orders allege erroneous refund of accumulated ITC under Rule 89 of CGST Rules for late 2022.
The dispute centers on whether domestic market values of similar goods should limit export refund amounts.
Aurobindo Pharma is challenging the validity of Rule 89(4)(C) in the Telangana High Court.
The company will file a fresh appeal before the Commissioner of Central Tax (Appeals), Hyderabad.

💡 Investors should monitor the legal proceedings as tax disputes are common in the sector; however, the immediate financial impact is limited given the company's scale. No immediate action is required as the company is actively contesting the demand.

Aurobindo Pharma Clarifies USFDA Inspection at Unit-VII Following Media Reports

🔵 WATCH ⭐ 7/10

REGULATORY 📅 18 Feb 2026, 01:33 PM

Aurobindo Pharma has issued a clarification to the stock exchanges regarding news reports of USFDA quality concerns at its Telangana-based Unit-VII. The company confirmed that the USFDA inspection at this facility concluded on February 10, 2026, and they are currently preparing a response to the observations within the stipulated timelines. Management maintains that these inspections are a routine part of global business operations and that all material information has already been disclosed. The stock had previously reacted to reports of these quality concerns, prompting the exchange's request for verification.

USFDA inspection at Unit-VII (Telangana) was completed on February 10, 2026
Company responded to NSE and BSE clarification requests on February 18, 2026
Management committed to responding to USFDA observations within the required regulatory timeframe
Company asserts that no additional material information remains undisclosed beyond the February 10 filing

💡 Investors should wait for details regarding the specific nature and severity of the USFDA observations (Form 483) for Unit-VII. The stock is likely to remain under pressure or volatile until the regulatory risk is fully quantified.

Aurobindo Pharma Q3 FY26: Revenue Up 8.4% to ₹8,646 Cr, Europe Growth Surges 27%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 16 Feb 2026, 11:24 AM

Aurobindo Pharma reported a steady Q3 FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 crores, driven by a robust 27% growth in the European business. EBITDA margins remained healthy at 20.5%, supported by lower raw material costs and a favorable business mix. The company is on track for its Pen-G plant ramp-up, targeting over 10,000 metric tonnes annually, and expects its European operations to surpass the $1 billion mark by the end of FY26. Management clarified that recent USFDA observations at the Eugia III facility are procedural and will not impact production.

Consolidated revenue increased 8.4% YoY to ₹8,646 crores with EBITDA at ₹1,773 crores (20.5% margin)
European formulation business grew 27% YoY to ₹2,703 crores, nearing a $1 billion annual run rate
US injectable sales rose 17% YoY, while overall US revenue stood at $420 million
Pen-G facility ramp-up is on track to reach 65-70% capacity by March 2026
Net profit reached ₹910 crores, despite a one-time ₹65 crore charge for labor code amendments

💡 Investors should monitor the ramp-up of the Pen-G facility and the commercialization of the Dayton plant in FY27 as key margin drivers. The stock remains a strong play on geographic diversification, particularly with the outperformance in Europe.

Aurobindo Pharma Subsidiary Receives US FDA Approval for ADQUEY Ointment

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 13 Feb 2026, 06:34 PM

Aurobindo Pharma's step-down subsidiary, Acrotech Biopharma, has secured US FDA approval for ADQUEY (difamilast 1%) ointment. This non-steroidal treatment is indicated for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older. The approval is backed by Phase III clinical trials showing significant improvement in patients over a 4-week treatment period compared to a placebo. This marks a strategic milestone for Aurobindo as it expands its proprietary medication portfolio in the high-value US dermatology market.

FDA approval granted for ADQUEY (difamilast 1%) for treating mild-to-moderate atopic dermatitis.
Indicated for both adults and pediatric patients as young as 2 years old.
Product is a novel, non-steroidal, topical phosphodiesterase 4 (PDE4) inhibitor.
Phase III trials demonstrated Investigator’s Global Assessment (IGA) success within 4 weeks of treatment.
Acrotech Biopharma has held the US license for this Otsuka Pharmaceutical-developed drug since 2021.

💡 Investors should view this as a positive development that strengthens Aurobindo's specialty branded portfolio in the US. Monitor the commercial launch timeline and market penetration, as branded products typically offer higher margins than generic counterparts.

View All AUROPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 6.3% YoY to INR 8,286 Cr in Q2 FY26. US Formulations grew 2% QoQ to USD 417 million (INR 3,634 Cr). Europe Formulations grew 17.8% YoY to INR 2,480 Cr. Growth Markets grew 8.7% YoY to INR 882 Cr. ARV Formulations surged 68.7% YoY to INR 325 Cr. API business declined 16.9% YoY to INR 961 Cr due to market pricing pressures.

Geographic Revenue Split

US Formulations account for 43.9% of consolidated revenue. Europe contributes approximately 30% (INR 2,480 Cr). Growth Markets represent 10.6% (INR 882 Cr). ARV and API segments contribute 3.9% and 11.6% respectively.

Profitability Margins

Gross Margin improved to 59.7% in Q2 FY26 from 58.8% in Q2 FY25 (up 88 bps), driven by favorable raw material prices and business mix. Net Profit Margin for FY25 stood at 11.0%.

EBITDA Margin

EBITDA for Q2 FY26 was INR 1,678 Cr, representing a 20.3% margin (up 16 bps YoY). Excluding gRevlimid, EBITDA grew 14% QoQ, reflecting strong operating leverage and cost efficiency.

Capital Expenditure

Net CapEx for Q2 FY26 was USD 106 million (approx. INR 890 Cr). The company has committed INR 1,000 Cr for the TheraNym mammalian bioreactor facility and is investing in a new vial filling line at CuraTeQ.

Credit Rating & Borrowing

Debt Equity Ratio is low at 0.08 as of March 2025. Average finance costs declined to 4.7% in Q2 FY26 due to effective treasury management. Interest Coverage Ratio stood at 12.2 in FY25.

⚙️ Operational Drivers

Raw Materials

Key inputs include Coal (for power in Pen-G plant), Beta-lactam intermediates (73% of API sales), and Non-Beta lactam intermediates. Specific chemical names are not disclosed in the available documents.

Import Sources

Sourcing includes China (for European supply ramp-up) and domestic Indian markets. Specific state-level sourcing is not disclosed.

Capacity Expansion

Pen-G facility (Lyfius) is ramping up to 15,000 MT capacity. TheraNym is establishing a 2x15 kL mammalian bioreactor facility expected to be ready by June/July 2026. China plant started invoicing in April 2025 with a goal of triple-digit turnover in 3 years.

Raw Material Costs

Raw material costs are optimized through backward integration (Pen-G plant), which is expected to push gross margins above 60% once fully operational. API pricing pressures impacted revenue by 16.9% YoY.

Manufacturing Efficiency

Fixed Asset Turnover was 2.1 in FY25. The company is targeting 100% capacity utilization at the Pen-G plant to reach 15,000 MT production.

📈 Strategic Growth

Expected Growth Rate

20-21%

Growth Strategy

Growth will be driven by the commercialization of the biosimilar portfolio (CuraTeQ), ramp-up of the Pen-G facility, and the Lannett acquisition in the US. The company aims for USD 1 billion in annual revenue from Europe by FY26 through increased in-house supplies and China plant exports.

Products & Services

Oral Solids, Injectables, Biosimilars (Trastuzumab, Bevacizumab, Denosumab, Omalizumab), ARV formulations, and APIs (Beta-lactam and Non-Beta lactam).

Brand Portfolio

Lyfius (Pen-G), CuraTeQ (Biosimilars), TheraNym (Biologics), Lannett (US acquisition).

New Products/Services

Launched 6 new products and filed 13 ANDAs in Q2 FY26. Biosimilars like Trastuzumab and Bevacizumab have received EC and MHRA approvals.

Market Expansion

Expanding in Growth Markets (Indonesia, China, Brazil, Mexico) and scaling the European business to reach a USD 1 billion milestone by FY26.

Strategic Alliances

Signed a second product contract with MSD (Merck) to support expanded scope in biologics, adding two 15 kL bioreactor lines.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and biosimilars. Aurobindo is positioning itself through CuraTeQ and TheraNym to capture the biologics CMO and biosimilar market.

Competitive Landscape

Faces competitive pricing pressures in the API and US generic markets.

Competitive Moat

Moat is built on vertical integration (Pen-G backward integration), a diversified global portfolio (US, Europe, Growth Markets), and a robust pipeline of 13 ANDA filings in a single quarter.

Macro Economic Sensitivity

Sensitive to movements in currency exchange and interest rates. The company reported a small FX gain of INR 5 Cr in Q2 FY26 compared to INR 15 Cr YoY.

Consumer Behavior

Increased demand for affordable ARVs and biosimilars globally is driving volume growth.

Geopolitical Risks

Trade barriers and stricter climate regulations pose transition risks and higher compliance costs.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA, European Commission, and MHRA (UK) regulations for product approvals and manufacturing facility inspections.

Environmental Compliance

The company is investing in energy-efficient technologies and conducting energy audits to align with carbon regulations.

Taxation Policy Impact

Reported tax rate is approximately 35% because tax credits are not taken on losses from new businesses (like Pen-G); the effective tax rate on profitable entities is 25%.